$ALKS
Alkermes plc.

2018 Q4 Form 10-Q Financial Statement

#000156459018024699 Filed on October 23, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $315.8M $248.7M $217.4M
YoY Change 14.67% 14.41% 20.64%
Cost Of Revenue $49.10M $39.41M $36.05M
YoY Change 27.53% 9.31% 1.56%
Gross Profit $266.6M $209.3M $181.3M
YoY Change 12.54% 15.43% 25.23%
Gross Profit Margin 84.42% 84.15% 83.41%
Selling, General & Admin $141.2M $128.8M $99.60M
YoY Change 27.32% 29.32% 9.33%
% of Gross Profit 52.96% 61.54% 54.93%
Research & Development $109.0M $101.3M $104.4M
YoY Change 4.31% -3.0% 5.03%
% of Gross Profit 40.89% 48.38% 57.57%
Depreciation & Amortization $25.90M $26.30M $25.00M
YoY Change 2.78% 5.2% 5.04%
% of Gross Profit 9.71% 12.57% 13.79%
Operating Expenses $266.6M $101.3M $219.6M
YoY Change 15.41% -53.89% 6.65%
Operating Profit $0.00 -$37.16M -$38.36M
YoY Change -100.0% -3.12% -37.22%
Interest Expense -$200.0K $3.346M $3.129M
YoY Change -88.89% 6.94% -225.16%
% of Operating Profit -223696213333333.3%
Other Income/Expense, Net -$1.500M $3.325M $2.566M
YoY Change -122.06% 29.58% -242.56%
Pretax Income -$1.700M -$33.83M -$35.79M
YoY Change -115.74% -5.47% -45.19%
Income Tax $8.000M $611.0K $486.0K
% Of Pretax Income
Net Earnings -$9.700M -$34.44M -$36.28M
YoY Change -1.02% -5.05% -42.14%
Net Earnings / Revenue -3.07% -13.85% -16.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$62.38K -$221.5K -$236.2K
COMMON SHARES
Basic Shares Outstanding 155.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $539.3M $467.1M $450.1M
YoY Change 24.4% 3.77% -18.09%
Cash & Equivalents $266.8M $216.0M $165.1M
Short-Term Investments $272.5M $251.0M $285.0M
Other Short-Term Assets $53.30M $50.30M $38.90M
YoY Change 9.9% 29.31% 48.47%
Inventory $90.20M $88.02M $85.00M
Prepaid Expenses
Receivables $300.5M $264.4M $207.5M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $983.3M $869.8M $781.6M
YoY Change 21.56% 11.28% -3.18%
LONG-TERM ASSETS
Property, Plant & Equipment $310.0M $303.1M $270.7M
YoY Change 8.87% 11.96% 3.24%
Goodwill $92.87M $92.87M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $86.20M $115.7M $125.1M
YoY Change -46.59% -7.51% 61.63%
Other Assets $16.14M $16.33M $206.3M
YoY Change 15.03% -92.08% 53.84%
Total Long-Term Assets $841.8M $891.0M $966.7M
YoY Change -14.84% -7.84% 7.4%
TOTAL ASSETS
Total Short-Term Assets $983.3M $869.8M $781.6M
Total Long-Term Assets $841.8M $891.0M $966.7M
Total Assets $1.825B $1.761B $1.748B
YoY Change 1.55% 0.71% 2.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $39.77M $44.11M $52.70M
YoY Change -28.38% -16.29% 20.32%
Accrued Expenses $294.0M $250.9M $198.5M
YoY Change 27.49% 26.4% 40.68%
Deferred Revenue $3.169M $6.916M
YoY Change 62.01%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.843M $2.843M $3.000M
YoY Change -5.23% -5.23% 0.0%
Total Short-Term Liabilities $339.8M $304.8M $256.0M
YoY Change 16.71% 19.06% 34.6%
LONG-TERM LIABILITIES
Long-Term Debt $276.5M $277.0M $279.0M
YoY Change -0.71% -0.71% -1.27%
Other Long-Term Liabilities $27.96M $23.19M $26.00M
YoY Change 45.58% -10.81% 4.42%
Total Long-Term Liabilities $304.4M $300.2M $305.0M
YoY Change 2.28% -1.57% -0.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $339.8M $304.8M $256.0M
Total Long-Term Liabilities $304.4M $300.2M $305.0M
Total Liabilities $653.7M $610.0M $561.0M
YoY Change 9.98% 8.73% 12.72%
SHAREHOLDERS EQUITY
Retained Earnings -$1.185B -$1.176B
YoY Change 13.5%
Common Stock $2.469B $2.435B
YoY Change 5.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.171B $1.151B $1.187B
YoY Change
Total Liabilities & Shareholders Equity $1.825B $1.761B $1.748B
YoY Change 1.55% 0.71% 2.4%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$9.700M -$34.44M -$36.28M
YoY Change -1.02% -5.05% -42.14%
Depreciation, Depletion And Amortization $25.90M $26.30M $25.00M
YoY Change 2.78% 5.2% 5.04%
Cash From Operating Activities $60.50M $33.50M $19.50M
YoY Change 68.52% 71.79% 32.65%
INVESTING ACTIVITIES
Capital Expenditures -$17.60M -$16.40M -$12.80M
YoY Change -1.12% 28.12% 11.3%
Acquisitions
YoY Change
Other Investing Activities $9.800M $42.50M -$800.0K
YoY Change 172.22% -5412.5% -101.37%
Cash From Investing Activities -$7.800M $26.10M -$13.60M
YoY Change -45.07% -291.91% -128.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000M 600.0K 1.100M
YoY Change -144.44% -45.45% -101.97%
NET CHANGE
Cash From Operating Activities 60.50M 33.50M 19.50M
Cash From Investing Activities -7.800M 26.10M -13.60M
Cash From Financing Activities -2.000M 600.0K 1.100M
Net Change In Cash 50.70M 60.20M 7.000M
YoY Change 93.51% 760.0% 20.69%
FREE CASH FLOW
Cash From Operating Activities $60.50M $33.50M $19.50M
Capital Expenditures -$17.60M -$16.40M -$12.80M
Free Cash Flow $78.10M $49.90M $32.30M
YoY Change 45.44% 54.49% 23.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
155382787
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
ALKS
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
216041000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191296000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
251046000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
242208000
CY2018Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
250913000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
233590000
CY2018Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
13476000
CY2017Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2018Q3 us-gaap Inventory Net
InventoryNet
88018000
CY2017Q4 us-gaap Inventory Net
InventoryNet
93275000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
304788000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16330000
CY2018Q3 us-gaap Assets
Assets
1760710000
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
295029000
CY2018Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6916000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2018Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2843000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
50265000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
303087000
CY2018Q3 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
92279000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
291122000
CY2018Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
277007000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
278436000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23190000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19204000
CY2018Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5010000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5657000
CY2018Q3 us-gaap Liabilities
Liabilities
609995000
CY2017Q4 us-gaap Liabilities
Liabilities
594419000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
1574000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1557000
CY2017Q3 us-gaap Interest Expense
InterestExpense
3129000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3287000
us-gaap Profit Loss
ProfitLoss
-129598000
us-gaap Profit Loss
ProfitLoss
-148156000
us-gaap Interest Expense
InterestExpense
11959000
CY2018Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
4200000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
808844000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
48475000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
869759000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284736000
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
207426000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
256168000
CY2018Q3 us-gaap Long Term Investments
LongTermInvestments
111456000
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
157212000
CY2018Q3 us-gaap Goodwill
Goodwill
92873000
CY2017Q4 us-gaap Goodwill
Goodwill
92873000
CY2018Q3 us-gaap Business Combination Contingent Consideration Asset Noncurrent
BusinessCombinationContingentConsiderationAssetNoncurrent
67500000
CY2017Q4 us-gaap Business Combination Contingent Consideration Asset Noncurrent
BusinessCombinationContingentConsiderationAssetNoncurrent
84800000
CY2017Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
98560000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14034000
CY2017Q4 us-gaap Assets
Assets
1797227000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
286166000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1956000
CY2018Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
105132000
CY2017Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
89347000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2433594000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2338755000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3666000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3792000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1175655000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1044365000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
1150715000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1202808000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1760710000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1797227000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
157674736
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
156057632
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
155363980
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154009456
CY2018Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2310756
CY2017Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2048176
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
248720000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
217385000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
778512000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
39410000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36054000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101265000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
310682000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
48742000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46417000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
255741000
us-gaap Costs And Expenses
CostsAndExpenses
877660000
us-gaap Costs And Expenses
CostsAndExpenses
781739000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-37158000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38356000
us-gaap Operating Income Loss
OperatingIncomeLoss
-99148000
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2561000
us-gaap Interest Expense
InterestExpense
8816000
CY2017Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
13600000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-17300000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
15900000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9078000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2815000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10696000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3325000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2566000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26128000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-325000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33833000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-35790000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-125276000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-154060000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
611000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
486000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4322000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5904000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-34444000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-36276000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
155328000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
153684000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
154979000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
153263000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
314000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
83000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
126000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34130000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36193000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129472000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-148134000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
95000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
35000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
42000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-14000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77758000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73305000
us-gaap Share Based Compensation
ShareBasedCompensation
76043000
us-gaap Share Based Compensation
ShareBasedCompensation
63336000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3879000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-11919000
us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
10471000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2298000
us-gaap Payments Of Debt Restructuring Costs
PaymentsOfDebtRestructuringCosts
2251000
us-gaap Other Noncash Expense
OtherNoncashExpense
1209000
us-gaap Other Noncash Expense
OtherNoncashExpense
3357000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
17322000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
16434000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
4366000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2596000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
21843000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
3291000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1944000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12899000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43430000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2485000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1102000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4321000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
6680000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
38768000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16719000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51841000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33482000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
428000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
50000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
307603000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
289226000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
344624000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
318492000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14392000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4166000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
18318000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
18298000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15785000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16418000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
743000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1421000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
369000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-370000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24745000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21255000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
191296000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186378000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216041000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165123000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
7117000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
5321000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:10pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. THE COMPANY</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. The Company has a diversified portfolio of marketed drug products and a clinical pipeline of product candidates that address CNS disorders such as schizophrenia, depression, addiction and MS. Headquartered in Dublin, Ireland,&#160;Alkermes&#160;has a research and development (&#8220;R&amp;D&#8221;) center in&#160;Waltham, Massachusetts; an R&amp;D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in&#160;Wilmington, Ohio.</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.7%;">The preparation of the Company&#8217;s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies, including those related to revenue recognition and related allowances, its collaborative relationships, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments, contingent consideration and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.</p></div>
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3309000
CY2018Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
11926000
CY2018Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
alks:PharmaceuticalMember
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2018Q3 alks Number Of Operating Leases
NumberOfOperatingLeases
2
CY2017Q4 alks Collaborative Arrangements Proceeds From Upfront Payment
CollaborativeArrangementsProceedsFromUpfrontPayment
28000000
CY2018Q2 alks Collaborative Arrangement Additional Payment Received
CollaborativeArrangementAdditionalPaymentReceived
50000000
CY2017Q4 alks Collaborative Arrangement Milestone Payments Entitled To Be Received Upon Approval Of New Drug Application By Food And Drug Administration
CollaborativeArrangementMilestonePaymentsEntitledToBeReceivedUponApprovalOfNewDrugApplicationByFoodAndDrugAdministration
150000000
CY2017Q4 alks Number Of Obligations Performed Initially
NumberOfObligationsPerformedInitially
4
CY2017Q4 alks Discounted Cash Flow Discounted Rate
DiscountedCashFlowDiscountedRate
0.080
CY2018Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
200000
CY2017Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
200000
CY2018Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9110000
alks Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
49387000
us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
45021000
CY2018Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9442000
alks Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
5793000
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
alks:PharmaceuticalMember
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34444000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-129598000
CY2018Q3 alks Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
363466000
CY2017Q4 alks Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
400486000
CY2018Q3 alks Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
173000
CY2017Q4 alks Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
227000
CY2018Q3 alks Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
772000
CY2017Q4 alks Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
920000
CY2018Q3 alks Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
365000
CY2017Q4 alks Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
373000
CY2018Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
362502000
CY2017Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
399420000
alks Marketable Securities Realized Gain
MarketableSecuritiesRealizedGain
4000
alks Marketable Securities Realized Gain
MarketableSecuritiesRealizedGain
9000
alks Marketable Securities Realized Loss
MarketableSecuritiesRealizedLoss
268000
alks Marketable Securities Realized Loss
MarketableSecuritiesRealizedLoss
3000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
212497000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
147482000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
359979000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
212078000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
146781000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
358859000
CY2018Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
1820000
CY2018Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
1667000
CY2018Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
3487000
CY2018Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
1820000
CY2018Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1823000
CY2018Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
3643000
alks Fair Value Recurring Basis Assets Or Liabilities Transfers Between Levels
FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevels
0
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
86195000
CY2018Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
68787000
CY2018Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
29859000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
29883000
CY2018Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
34872000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
38964000
CY2018Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
23287000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
24428000
CY2018Q3 alks Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
16200000
CY2017Q4 alks Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
8700000
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
571637000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
524794000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
268550000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
240058000
CY2018Q3 us-gaap Goodwill Gross
GoodwillGross
92873000
CY2018Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
582750000
CY2018Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
375324000
CY2018Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
65000000
CY2018Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
55000000
CY2018Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
50000000
CY2018Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
40000000
CY2018Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
35000000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
44114000
CY2018Q3 us-gaap Due To Employees Current
DueToEmployeesCurrent
60472000
CY2017Q4 us-gaap Due To Employees Current
DueToEmployeesCurrent
54568000
CY2018Q3 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
131067000
CY2017Q4 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
111137000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59376000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
64935000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
55526000
alks Number Of Lender Holding Percentage Of Outstanding Amount
NumberOfLenderHoldingPercentageOfOutstandingAmount
1
alks Percentage Of Outstanding Principal Amount Held By Lender
PercentageOfOutstandingPrincipalAmountHeldByLender
0.01
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25068000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19488000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76043000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
63336000
alks Number Of Phase3 Studies
NumberOfPhase3Studies
2
alks Performance Period From Date Of Grant
PerformancePeriodFromDateOfGrant
P3Y
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14231000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11771000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12895000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11622000
CY2018Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
220000
CY2018Q1 alks Operating Lease Provision For Extension Of Term
OperatingLeaseProvisionForExtensionOfTerm
P10Y
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
alks Number Of Separate Paragraph Four Notices
NumberOfSeparateParagraphFourNotices
11
alks Maximum Period For Lawsuit Related To Paragraph Four Certification Notice
MaximumPeriodForLawsuitRelatedToParagraphFourCertificationNotice
P45D
alks Minimum Period Before Fda Can Approve Patent Request
MinimumPeriodBeforeFdaCanApprovePatentRequest
P30M
alks Number Of Abbreviated New Drug Application Filers Consolidated To Single Case
NumberOfAbbreviatedNewDrugApplicationFilersConsolidatedToSingleCase
8

Files In Submission

Name View Source Status
0001564590-18-024699-index-headers.html Edgar Link pending
0001564590-18-024699-index.html Edgar Link pending
0001564590-18-024699.txt Edgar Link pending
0001564590-18-024699-xbrl.zip Edgar Link pending
alks-10q_20180930.htm Edgar Link pending
alks-20180930.xml Edgar Link completed
alks-20180930.xsd Edgar Link pending
alks-20180930_cal.xml Edgar Link unprocessable
alks-20180930_def.xml Edgar Link unprocessable
alks-20180930_lab.xml Edgar Link unprocessable
alks-20180930_pre.xml Edgar Link unprocessable
alks-ex1010_39.htm Edgar Link pending
alks-ex1011_41.htm Edgar Link pending
alks-ex1012_100.htm Edgar Link pending
alks-ex101_30.htm Edgar Link pending
alks-ex102_31.htm Edgar Link pending
alks-ex103_32.htm Edgar Link pending
alks-ex104_33.htm Edgar Link pending
alks-ex105_34.htm Edgar Link pending
alks-ex106_35.htm Edgar Link pending
alks-ex107_36.htm Edgar Link pending
alks-ex108_37.htm Edgar Link pending
alks-ex109_38.htm Edgar Link pending
alks-ex311_8.htm Edgar Link pending
alks-ex312_6.htm Edgar Link pending
alks-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gduhxos1x1cd000001.jpg Edgar Link pending
gduhxos1x1cd000002.jpg Edgar Link pending
gduhxos1x1cd000003.jpg Edgar Link pending
gduhxos1x1cd000004.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending